MarketInOut Stock Screener Log In | Sign Up
 

Viridian Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 09/11/2026
Viridian Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,406.33 mln
Float109 mln
Earnings Date11/16/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

208
Highly suspicious

1-Year Forecast

36.62
Transformational upside

Relative Strength

14 / 100
Significantly lagging

Debt / Equity

0.37
Low leverage

Pre-Tax Margin

-544%
Severely loss-making

Business Description

Viridian Therapeutics is a biopharmaceutical company focused on developing medicines for rare and serious conditions, with a particular emphasis on thyroid eye disease and Graves' disease. The company is advancing several drug candidates that work by blocking specific proteins involved in these conditions, including treatments given by injection under the skin as well as through a vein. Founded in 2010 and based in Waltham, Massachusetts, the company rebranded from Miragen Therapeutics in 2021.

Key Fundamentals

EPS-3.40
ROE-63.68
RPS0.74
ROIC-1,158
ROA-49.04
Interest Cover-21.40
EBITDA, mln-371
EV / EBITDA-5.33
EV / EBIT-5.32
Revenue, mln71.13
EV / Revenue27.77

Financial Strength

Altman Z-Score1.66
Piotroski F-Score 3 / 9
Beneish M-Score208
1-Year Target Price36.62
Short Ratio12.04
Short % of Float17.85

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -7.49% 13 / 100   
1 Month -7.17% 24 / 100   
2 Months 28.18% 93 / 100   
6 Months -25.24% 17 / 100   
1 Year 7.16% 55 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us